Skip to main content
Contact Us
Subscribe
E-Edition
85°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
9.400
+0.840 (+9.81%)
Streaming Delayed Price
Updated: 12:26 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study
January 18, 2023
Via
Investor Brand Network
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
January 18, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004
January 12, 2023
Via
Investor Brand Network
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
January 12, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs
January 09, 2023
Via
Investor Brand Network
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
January 08, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’
December 20, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Highlights 2022 Accomplishments and Milestones
December 20, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Presents CYB003 Preclinical Data Amongst Leading Scientists, Academics in Neuropsychopharmacology
December 07, 2022
Via
Investor Brand Network
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
December 06, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022
November 15, 2022
Via
Investor Brand Network
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
November 15, 2022
From
Cybin Inc.
Via
Business Wire
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
November 14, 2022
From
Cybin Inc.
Via
Business Wire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
November 14, 2022
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Retirement
Exposures
Pension
Product Safety
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Progress on Clinical Path for CYB004
November 10, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
November 10, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events
November 03, 2022
Via
Investor Brand Network
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
November 03, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit
November 01, 2022
Via
Investor Brand Network
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
November 01, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators
October 27, 2022
Via
Investor Brand Network
Cybin’s EMBARK Program Announces Graduation of Facilitators
October 27, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients
October 17, 2022
Via
Investor Brand Network
TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), The Chopra Foundation Note World Mental Health Day
October 11, 2022
Via
Investor Brand Network
Psychedelic Drugs Prove Their Worth In Clinical Trials
October 11, 2022
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial...
Via
PressReach
Cybin & The Chopra Foundation Recognize World Mental Health Day
October 10, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ‘Focused on Adding Targeted IP’
October 06, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Provides Update on its Intellectual Property Portfolio
October 06, 2022
From
Cybin Inc.
Via
Business Wire
Colorado to Vote on Legalizing Psychoactives in November
October 05, 2022
Voters in Colorado will have a say in the legalization of psychedelic drugs this November as an initiative to legalize psilocybin mushrooms and other naturally occurring psychedelics appears on the...
Via
PressReach
Topics
Supply Chain
Exposures
Supply Chain
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds
September 27, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.